CY-503

DRUG2 trials

Sponsors

Cytavis Biopharma GmbH

Conditions

MelanomaMetastatic Colorectal Cancer

Phase 2

CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy

CompletedNCT00658437

Cytavis Biopharma GmbHMelanoma

Start: 2008-04-30End: 2010-05-31Updated: 2011-06-08

CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer

TerminatedNCT00932724

Cytavis Biopharma GmbHMetastatic Colorectal Cancer

Start: 2009-07-31End: 2012-08-31Updated: 2013-07-10

Related Papers

Aviscumine (ME-503)-Skin Reaction as significant Factor for its Efficacy Expanded Evaluation of the Results from the Phase II Trial NCT00658437

Immunotherapy Open Access2017-01-011 citations

Abstract CT123: Aviscumine (ME-503), a plant protein with a novel mode of action, shows clinical activity in unresectable stage IV metastatic melanoma: data from a phase II trial

Cancer Research2016-07-15

Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study

Journal for ImmunoTherapy of Cancer2014-07-298 citations